Adult Acute Monoblastic Leukemia: Clinical Trials

5 trials for Adult Acute Monoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 active not recruiting. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Active not recruiting 2

Follow Adult Acute Monoblastic Leukemia: new trials by email Literature Review of Adult Acute Monoblastic Leukemia trials Research Report on Adult Acute Monoblastic Leukemia

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Phase 2CompletedNational Cancer Institute (NCI)322013-05-012016-09-01
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Cytarabine, Daunorubicin Hydrochloride, Decitabine - Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia
Phase 2Active not recruitingNational Cancer Institute (NCI)1782011-09-162026-04-27
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
Tipifarnib, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Phase 2CompletedNational Cancer Institute (NCI)212011-05-012015-04-08
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia
Phase 2CompletedNational Cancer Institute (NCI)682010-07-152022-08-04
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Azacitidine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia
Phase 2Active not recruitingNational Cancer Institute (NCI)1332008-12-012026-10-22

Narrower conditions

Leukemia, Monocytic, Acute (5)  ·  Leukemia, Myeloid, Acute (5)  ·  Leukemia, Myelomonocytic, Acute (5)  ·  Leukemia, Erythroblastic, Acute (4)  ·  Leukemia, Megakaryoblastic, Acute (4)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Leukemia, Basophilic, Acute (1)  ·  Myelodysplastic Syndromes (1)

Broader conditions

Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Leukemia (5)  ·  Leukemia, Myeloid (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Bone Marrow Diseases (4)  ·  Myeloproliferative Disorders (4)  ·  Anemia (1)  ·  Anemia, Refractory (1)

Interventions

Azacitidine (2)  ·  Cytarabine (2)  ·  Antilymphocyte Serum (1)  ·  Busulfan (1)  ·  Daunorubicin (1)  ·  Decitabine (1)  ·  Gemtuzumab (1)  ·  Injections (1)  ·  MK-8776 (1)  ·  Methotrexate (1)  ·  Stem Cell Transplantation (1)  ·  Tacrolimus (1)  ·  fludarabine phosphate (1)  ·  merphos (1)  ·  tipifarnib (1)

Sponsors

National Cancer Institute (NCI) (5)

Countries

United States (5)

Top investigators

B. Smith (1)  ·  Jeffrey Lancet (1)  ·  Joseph M Scandura (1)  ·  Ravi Vij (1)  ·  Sucha Nand (1)

Results publications

PMID 24092933, PMID 31212080

NIH funding

U01CA070095 (2), N01CM00070 (1), N01CM00071 (1), N01CM00100 (1), N01CM62204 (1), P30CA006973 (1), P30CA076292 (1), U10CA031946 (1), U10CA032102 (1), U10CA180821 (1)